Where Progress Lives: This Month in California Life Sciences April 2026
- From Genentech’s 50th anniversary to Biogen’s West Coast expansion to the San Mateo Progress Seminar, April offered a compelling look at the depth and ambition of California’s life sciences ecosystem.
- SBIR/STTR reauthorization is now law, unlocking nearly $6 billion in frozen funding for early-stage biotech companies.
- CMS and FDA announced their new RAPID coverage pathway, a promising step toward accelerating Medicare access to breakthrough medical devices.
- CLS and HUB International Life Sciences brought HR and operations leaders together for Beyond the Tipping Point, giving growing companies access to strategic benefits thinking that helps them compete for world-class talent.
- San Diego’s life sciences community gathered at Nautilus for SoCal Social, an Earth Day celebration that brought together sustainability-minded professionals from across the ecosystem for an evening of connection and community.
Each month, California Life Sciences (CLS) President and CEO Mike Guerra shares what’s shaping the life sciences industry, highlights the conversations that matter most to members, and offers a window into what the CLS team is working on.
April brought a full calendar of events and some important milestones, from important policy progress in Washington to a celebration of 50 years of industry-defining innovation that began right here in California.
California’s ecosystem: extraordinary by design
On April 13, CLS and Genentech co-hosted life sciences leaders, policymakers, and health advocates at Genentech’s South San Francisco campus to celebrate the 50 years of biotech innovation in California. We discussed the state of the industry, the breakthroughs that provide hope for millions of patients around the world, and how they are a result of decades of bold California science and industry partnership with government at all levels.
Just days later, we joined Biogen at the ribbon cutting for their expanded West Coast Hub in South San Francisco, a 100-plus employee facility reflecting the depth of research talent, world-class institutions, and scientific community that makes California the global destination for life sciences innovation.
On April 20, I joined leaders from Genentech and Ultragenyx, and Asm. Diane Papan and Rep. Kevin Mullin in the birthplace of biotech for the San Mateo County Progress Seminar. We discussed what it takes to sustain biotech leadership in a rapidly evolving global landscape, and the importance of protecting the ecosystem that has made California the envy of the world.
April gave us a series of moments that captured exactly what California’s life sciences legacy looks like today. Fifty years in, this is still where the world comes to do something extraordinary.
Policy Progress in Washington D.C.
After a five-month lapse that left nearly $6 billion in frozen funding in limbo for small, innovative companies, SBIR/STTR reauthorization is now law. This is a meaningful victory for the early-stage companies that rely on these programs to fund the science that eventually reaches patients, and CLS was proud to advocate for it throughout the process.
This month, the Centers for Medicare & Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a new initiative designed to accelerate Medicare coverage of FDA-authorized Breakthrough Devices. CLS will actively engage in the forthcoming public comment period and continue working with policymakers to ensure patients can access the breakthrough technologies they need without delay. Read my full statement on the RAPID pathway to learn more.
Building a stronger, more connected life sciences community
April was a reminder that the California Life Sciences community comes together around more than just science. On April 8 in South San Francisco and April 9 in San Diego, CLS and HUB International Life Sciences hosted Beyond the Tipping Point, bringing HR, finance, and operations leaders together with experts from Milliman, McKinsey Global Institute, and ParetoHealth. These insightful conversations gave growing companies access to the kind of strategic benefits thinking that helps them compete for world-class talent without losing focus on the work that matters most. In San Diego, we were joined by Rick Neale, Executive Vice President and Chief Business Development and Growth Officer at Scripps Health, who offered a candid perspective on navigating the health system landscape.
On April 22, we brought the San Diego life sciences community together at Nautilus for SoCal Social, an Earth Day celebration built around the idea that environmental progress and scientific innovation go hand in hand. A vendor showcase featuring forward-thinking organizations from across our ecosystem, lawn games, and Earth Day-inspired food and drinks made for an evening that was equal parts meaningful and energizing. Thank you to our sponsors, American Laboratory Trading (ALT), Agilent, Clean Harbors, Corning, Corporate Traveler, Erlab, Kilroy, and VWR (Avantor), and to every attendee, vendor, and partner who made it a night worth celebrating. We’re looking forward to seeing you next year.
Looking Ahead
April was a full and meaningful month for our community. The companies building their future in California, from Genentech’s 50 years of industry-defining science to Biogen’s expanding West Coast presence, are a testament to what this ecosystem has produced and continues to attract. The policy progress in Washington, from SBIR/STTR reauthorization to our engagement on the RAPID coverage pathway, reflects the ongoing work of ensuring that the innovation happening here reaches patients who need it. Conversations at events like Beyond the Tipping Point and SoCal Social are a reminder that the strength of this community is built as much outside the lab as inside it.
I am grateful for the colleagues and partners who make all of this possible, and I look forward to sharing more next month.
Mike Guerra is President and CEO of California Life Sciences (CLS), California’s most influential life sciences trade association, representing more than 1,300 member companies. He chairs the Council of State Bioscience Associations and sits on multiple industry boards, working to advance California’s position as the world’s leading life sciences innovation ecosystem. Mike champions effective public policy at the national, state, and local levels, and is a steadfast advocate for the entrepreneurs and businesses driving life sciences forward in California.